Cyteir Therapeutics Names Krisztina Nemenyi as Senior Vice President of Regulatory Affairs and Quality
Cyteir Therapeutics (NASDAQ: CYT) has appointed Krisztina Nemenyi, PhD, as Senior Vice President of Regulatory Affairs and Quality. Nemenyi brings over 20 years of experience in regulatory functions within the pharmaceutical industry, including significant roles at Takeda and Bristol Myers Squibb. Her expertise will support the advancement of Cyteir's lead candidate, CYT-0851, currently in Phase 1/2 clinical trials for cancer treatment. The company aims to navigate the regulatory landscape efficiently to potentially achieve product registration.
- Appointment of experienced regulatory leader Krisztina Nemenyi will enhance oversight of CYT-0851's clinical advancement.
- Nemenyi's extensive background in oncology regulatory affairs may improve the likelihood of successful clinical trial navigation.
- None.
“Krisztina has an impressive track record of leading regulatory functions and development teams at global pharmaceutical companies to successful worldwide product registrations in oncology, demonstrating extensive knowledge of global clinical trial approval processes and requirements, strategic thinking about development plans that maximize the likelihood of successful regulatory applications, and effective and successful interactions with regulators throughout the product life cycle from IND to post approval,” said
“This is an exciting time to be joining Cyteir with CYT-0851 advancing in clinical studies,” said
About
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. At Cyteir, we employ an integrated target discovery approach that incorporates a critical evaluation of the target biology with internal and external information from a variety of genetic and chemical synthetic lethality screens to fuel our drug discovery and development pipeline. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors. Follow Cyteir on social media: LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005579/en/
INVESTOR CONTACT:
Vice President, Investor Relations and Corporate Communications
908-868-8926
Lisa.Hayes@cyteir.com
MEDIA CONTACT:
925-429-1850
mparisi@forwardhealthinc.com
Source:
FAQ
Who has been appointed as Senior Vice President of Regulatory Affairs at Cyteir Therapeutics?
What is the lead candidate of Cyteir Therapeutics?
What experience does Krisztina Nemenyi bring to Cyteir Therapeutics?